Hispanics Are at Highest Risk of Neurotoxicity From Chemotherapy for ALL

Audrey Sternberg
Published: Monday, Nov 12, 2018
Michael E. Scheurer, PhD, MPH

Michael E. Scheurer, PhD, MPH

Ethnic differences in the prevalence of neurotoxicity from methotrexate therapy may help explain why minority patients, specifically Hispanics, experience disparities in treatment outcomes for pediatric acute lymphoblastic leukemia (ALL), according to study results published in Clinical Cancer Research.1

Limitations to the study include its short timeline, said Scheurer, since there are insufficient data to evaluate the long-term effects of neurotoxicity. A larger study with more non-Hispanic black and Asian patients would help investigators better understand the issue, he added.

References

  1. Taylor OA, Brown AL, Brackett J, et al. Disparities in neurotoxicity risk and outcomes among pediatric acute lymphoblastic leukemia patients. Clin Cancer Res. 2018;24(20):5012-5017. doi: 10.1158/1078-0432.CCR-18-0939.
  2. Hispanic children more likely to experience neurotoxicity during treatment for acute lymphoblastic leukemia [news release]. Philadelphia, PA: American Association for Cancer Research; September 11, 2018. aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=1218. Accessed October 4, 2018.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x